Shes achieved 8% weight loss and HbA1c reduction from 8.1% to 7.2% over 4 months
What makes MEDVi unique is the combination of affordability, personalized care, and accessibility
People who are allergic to GLP
Puerarin alleviates depressive-like behaviors in high-fat diet-induced diabetic mice via modulating hippocampal GLP-1R/BDNF/TrkB signaling
In mice with acute myocardial infarction, liraglutide treatment decreased atrial IL6 expression and circulating IL-6 levels
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets